CA 19-9 As a Marker in Addition to CEA to Monitor Colorectal Cancer

Micro-Abstract Carcinoma antigen (CA) 19-9 can be a tumor marker in addition to carcinoembryonic antigen (CEA) in the follow-up of patients with colorectal cancer. In the 7.3% of the patients who have increases of only CA 19-9, the tumor marker can be an alternative to CEA. Besides, preoperative inc...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2014-12, Vol.13 (4), p.239-244
Main Authors: Stiksma, Jolanda, Grootendorst, Diana C, van der Linden, Peter Willem G
Format: Article
Language:English
Subjects:
Aged
Biomarkers, Tumor - blood
CA-19-9 Antigen - blood
CA19-9
Carcinoembryonic Antigen - blood
CEA
Colorectal Neoplasms - blood
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Female
Follow-up
Follow-Up Studies
Gastroenterology and Hepatology
Hematology, Oncology and Palliative Medicine
Humans
Immunoassay
Liver Neoplasms - blood
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Lung Neoplasms - blood
Lung Neoplasms - mortality
Lung Neoplasms - secondary
Lymphatic Metastasis
Male
Neoplasm Staging
Pre-operative
Prognosis
Retrospective Studies
Survival Rate
Tumor markers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Carcinoma antigen (CA) 19-9 can be a tumor marker in addition to carcinoembryonic antigen (CEA) in the follow-up of patients with colorectal cancer. In the 7.3% of the patients who have increases of only CA 19-9, the tumor marker can be an alternative to CEA. Besides, preoperative increased levels of CA 19-9 predict a poor survival.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2014.09.004